Good morning :)
Place Order
Add to Watchlist

Shukra Pharmaceuticals Ltd

SHUKRAPHAR Share Price

40.351.13% (+0.45)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹1,733 cr, stock is ranked 1,230

High Risk

Stock is 4.03x as volatile as Nifty

SHUKRAPHAR Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹1,733 cr, stock is ranked 1,230

High Risk

Stock is 4.03x as volatile as Nifty

SHUKRAPHAR Performance & Key Metrics

SHUKRAPHAR Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
145.0727.590.03%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.945.830.58%

SHUKRAPHAR Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

SHUKRAPHAR Company Profile

Shukra Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceuticals Products.

SHUKRAPHAR Similar Stocks (Peers)

Compare with peers Compare with peers 

SHUKRAPHAR Similar Stocks (Peers)

Compare with peers Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
Cipla Ltd
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
Lupin Ltd
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
Compare with Peers

SHUKRAPHAR Forecast

SHUKRAPHAR Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

SHUKRAPHAR

SHUKRAPHAR

Income

Balance Sheet

Cash Flow

SHUKRAPHAR Income Statement

SHUKRAPHAR Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 25.23%, vs industry avg of 10.03%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0% to 0.01%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 243.61%, vs industry avg of 20.02%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue5.215.485.7011.9511.5620.5760.0377.3936.8040.42
Raw Materialssubtract0.950.891.163.332.9611.0845.6543.7811.7522.97
Power & Fuel Costsubtract0.260.290.341.641.780.000.000.000.00
Employee Costsubtract1.051.231.914.343.754.574.415.025.47
Selling & Administrative Expensessubtract0.921.200.711.211.362.443.385.155.83
Operating & Other expensessubtract0.490.15-0.11-0.210.10-0.490.031.21-3.18
Depreciation/Amortizationsubtract0.470.740.961.481.471.661.842.053.003.24
Interest & Other Itemssubtract0.010.040.000.000.030.290.280.290.590.98
Taxes & Other Itemssubtract0.550.420.270.14-0.090.270.041.343.761.28
EPS0.020.020.020.000.010.020.240.740.220.27
DPS0.000.000.000.000.000.000.010.030.010.01
Payout ratio0.150.150.170.000.000.100.050.030.050.04
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

SHUKRAPHAR Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

SHUKRAPHAR Stock Peers

SHUKRAPHAR Past Performance & Peer Comparison

SHUKRAPHAR Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Shukra Pharmaceuticals Ltd180.9627.590.03%
Sun Pharmaceutical Industries Ltd39.926.020.88%
Torrent Pharmaceuticals Ltd67.2116.920.84%
Cipla Ltd23.303.931.05%

SHUKRAPHAR Stock Price Comparison

Compare SHUKRAPHAR with any stock or ETF
Compare SHUKRAPHAR with any stock or ETF
SHUKRAPHAR
Loading...

SHUKRAPHAR Holdings

SHUKRAPHAR Shareholdings

SHUKRAPHAR Promoter Holdings Trend

SHUKRAPHAR Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SHUKRAPHAR Institutional Holdings Trend

SHUKRAPHAR Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SHUKRAPHAR Shareholding Pattern

SHUKRAPHAR Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.96%0.00%0.11%0.00%48.93%

Dec 2024

Mar 2025

Jun 2025

Sep 2025

SHUKRAPHAR Shareholding History

SHUKRAPHAR Shareholding History

JunSepDec '24MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

SHUKRAPHAR Insider Trades & Bulk Stock Deals

SHUKRAPHAR Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SHUKRAPHAR stock

smallcases containing SHUKRAPHAR stock

Looks like this stock is not in any smallcase yet.

SHUKRAPHAR Events

SHUKRAPHAR Events

SHUKRAPHAR Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

SHUKRAPHAR Dividend Trend

No dividend trend available

SHUKRAPHAR Upcoming Dividends

SHUKRAPHAR Upcoming Dividends

No upcoming dividends are available

SHUKRAPHAR Past Dividends

SHUKRAPHAR Past Dividends

Cash Dividend

Ex DateEx DateSep 18, 2025

Final
Final | Div/Share: ₹0.01

Dividend/Share

₹0.01

Ex DateEx Date

Sep 18, 2025

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 15, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 15, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 19, 2019

SHUKRAPHAR Stock News & Opinions

SHUKRAPHAR Stock News & Opinions

Earnings
Shukra Pharmaceuticals standalone net profit rises 340.74% in the September 2025 quarter

Net profit of Shukra Pharmaceuticals rose 340.74% to Rs 2.38 crore in the quarter ended September 2025 as against Rs 0.54 crore during the previous quarter ended September 2024. Sales rose 5.76% to Rs 5.88 crore in the quarter ended September 2025 as against Rs 5.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales5.885.56 6 OPM %-6.9712.05 - PBDT1.011.58 -36 PBT0.200.88 -77 NP2.380.54 341 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to declare Quarterly Results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules EGM

Shukra Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 1 November 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to discuss results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 October 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to hold AGM

Shukra Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules AGM

Shukra Pharmaceuticals announced that the 32th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals wins contract worth Rs 24 cr from HSCC (India)

Shukra Pharmaceuticals has been awarded a prestigious contract by HSCC (India) (a Government of India Enterprise under the Ministry of Housing & Urban Affairs), acting on behalf of the Ministry of External Affairs, Government of India. The Company has received a Letter of Award (LoA) on dated 28 August 2025 for the supply of Medicines and Diagnostic Kits to Afghanistan (Technical Mission of India, Kabul, Afghanistan). The Letter of Award entails a total contract value of Rs 24.06 crore for the supply of essential Medicines and Diagnostic Kits, which includes packing, forwarding, insurance, and delivery at the consignee site in Afghanistan. This order further strengthens Shukra Pharmaceuticals Limited's international presence and reaffirms the Company's capabilities to execute large-scale global healthcare supply projects, especially under Government of India backed initiatives.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Shukra Pharmaceuticals standalone net profit rises 110.20% in the June 2025 quarter

Net profit of Shukra Pharmaceuticals rose 110.20% to Rs 1.03 crore in the quarter ended June 2025 as against Rs 0.49 crore during the previous quarter ended June 2024. Sales rose 69.50% to Rs 5.39 crore in the quarter ended June 2025 as against Rs 3.18 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales5.393.18 69 OPM %24.6825.79 - PBDT2.171.48 47 PBT1.380.81 70 NP1.030.49 110 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals announces board meeting date

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of Shukra Pharmaceuticals recommends Final Dividend

Shukra Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 04 June 2025, has recommended a Final Dividend of Rs.0.01 per share (i.e.1%), subject to the approval of the shareholders.Powered by Capital Market - Live

6 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) today?

    The share price of SHUKRAPHAR as on 5th December 2025 is ₹40.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?

    The past returns of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share are
    • Past 1 week: 3.65%
    • Past 1 month: -2.61%
    • Past 3 months: 40.69%
    • Past 6 months: 200.90%
    • Past 1 year: 545.63%
    • Past 3 years: 4707.23%
    • Past 5 years: 22066.67%

  3. What are the peers or stocks similar to Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?

    The peers or stocks similar to Shukra Pharmaceuticals Ltd (SHUKRAPHAR) include:

  4. What is the dividend yield % of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?

    The current dividend yield of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is 0.03.

  5. What is the market cap of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is ₹1733.56 Cr as of 5th December 2025.

  6. What is the 52 week high and low of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) share?

    The 52-week high of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is ₹44.31 and the 52-week low is ₹6.

  7. What is the PE and PB ratio of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) stock?

    The P/E (price-to-earnings) ratio of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is 180.96. The P/B (price-to-book) ratio is 27.59.

  8. Which sector does Shukra Pharmaceuticals Ltd (SHUKRAPHAR) belong to?

    Shukra Pharmaceuticals Ltd (SHUKRAPHAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Shukra Pharmaceuticals Ltd (SHUKRAPHAR) shares?

    You can directly buy Shukra Pharmaceuticals Ltd (SHUKRAPHAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.